title: Effects of dexamethasone and meloxicam on bovine CD25+ CD8+ and CD25- CD8+ T cells--in vitro study.
abstract: The aim of undertaken research was an in vitro evaluation of the effects of dexamethasone and meloxicam on selected bovine CD8(+) T lymphocyte subpopulations. Dexamethasone induced a fast-occurring and lasting depletion of CD25(-)CD8(+) cells. This was primarily the result of the proapoptotic effect of dexamethasone, but the antiproliferative effect of the drug was clearly responsible for the deepening of this disturbance. Dexamethasone transiently increased the relative and absolute CD25(high)CD8(+) and CD25(low)CD8(+) cell numbers. This effect was not a consequence of increased proliferation, but at least partly resulted from the antiapoptotic effect of the drug on these cells. The obtained results indicate that induction of CD8(+) lymphocyte depletion and impairment of IFN-γ production by these cells participate in the production of the anti-inflammatory and immunosuppressive effect of dexamethasone in cattle. An increase in Foxp3, IL-10 and TGF-β production by CD8(+) lymphocytes is not involved in the production of these effects because the drug did not affect the percentage of TGF-β(+)CD8(+) cells, while paradoxically reducing the percentage of cells with the suppressive phenotype, i.e. IL-10(+)CD25(low)CD8(+) and Foxp3(+)CD25(low)CD8(+) cells. Meloxicam did not substantially affect CD8(+) lymphocytes as to their percentage, absolute number, apoptosis, proliferation, Foxp3 expression and IFN-γ, IL-10 and TGF-β production. Thus, in the context of the parameters being estimated, meloxicam seems a relatively safe anti-inflammatory drug to be used in infectious diseases in cattle.
authors.affiliation: Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Warmia and Mazury, Oczapowski Street 13, 10-718 Olsztyn, Poland. tomasz.maslanka@uwm.edu.pl
authors.forename: Tomasz
authors.initials: T
authors.lastname: Maślanka
authors.forename: Jerzy J
authors.initials: JJ
authors.lastname: Jaroszewski
authors.forename: Włodzimierz
authors.initials: W
authors.lastname: Markiewicz
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Jasiecka
authors.forename: Hubert
authors.initials: H
authors.lastname: Ziółkowski
authors.forename: Dawid
authors.initials: D
authors.lastname: Jędrzkiewicz
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects* / Q000378:metabolism; D002417:Cattle; D002478:Cells, Cultured; D003907:Dexamethasone / Q000494:pharmacology*; D005260:Female; D005434:Flow Cytometry / Q000662:veterinary; D066298:In Vitro Techniques; D007371:Interferon-gamma / Q000096:biosynthesis; D016753:Interleukin-10 / Q000096:biosynthesis; D053645:Interleukin-2 Receptor alpha Subunit; D000077239:Meloxicam; D016176:T-Lymphocyte Subsets / Q000187:drug effects* / Q000378:metabolism; D013843:Thiazines / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*; D016212:Transforming Growth Factor beta / Q000096:biosynthesis
chemical_list: D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D053645:Interleukin-2 Receptor alpha Subunit; D013843:Thiazines; D013844:Thiazoles; D016212:Transforming Growth Factor beta; D016753:Interleukin-10; D003907:Dexamethasone; D007371:Interferon-gamma; D000077239:Meloxicam